[HTML] nature.com

[HTML][HTML] Proactive monitoring of drug–drug interactions between direct oral anticoagulants and small-molecule inhibitors in patients with non-small cell lung cancer

JL Gulikers, LS Otten, LEL Hendriks… - British Journal of …, 2024 - nature.com
Abstract Background Small-molecule inhibitors (SMIs) have revolutionised the treatment of
non-small cell lung cancer (NSCLC). However, SMI-induced drug–drug interactions (DDIs) …
相关文章

Proactive monitoring of drug-drug interactions between direct oral anticoagulants and small-molecule inhibitors in patients with non-small cell lung cancer.

JL Gulikers, LS Otten, LEL Hendriks… - British Journal of …, 2024 - europepmc.org
Background Small-molecule inhibitors (SMIs) have revolutionised the treatment of non-small
cell lung cancer (NSCLC). However, SMI-induced drug-drug interactions (DDIs) with …

Proactive monitoring of drug-drug interactions between direct oral anticoagulants and small-molecule inhibitors in patients with non-small cell lung cancer

JL Gulikers, LS Otten, LEL Hendriks… - British journal of … - pubmed.ncbi.nlm.nih.gov
Background Small-molecule inhibitors (SMIs) have revolutionised the treatment of non-small
cell lung cancer (NSCLC). However, SMI-induced drug-drug interactions (DDIs) with …